MIDATECH PHARMA
R&D | Glioblastoma (GBM)

Glioma of the brain in either children or adults are amongst the most aggressive cancers, with very limited and poor treatment options that are either ineffective or too toxic to be of benefit to patients. Survival is in the region of 9 – 12 months, and less than 5% survive through to 5 years. Midatech GNPs and other agents are being designed and/or evaluated for their ability to treat brain tumours via both systemic administration and/or local delivery directly into the tumour. Systemically, GNP’s may take targeting and therapeutic agents across the Blood Brain Barrier (BBB) when agents are administered intravenously. In addition to this systemic approach, Midatech is actively pursuing local delivery directly into the tumour through a technique referred to as Convection Enhanced Delivery (CED). CED bypasses the BBB and delivers therapeutic constructs directly into the tumour via a series of catheters fixed into the substance of the tumours.
 
The developed GNP constructs thus are capable of modifying both the efficacy and toxicity profile of existing therapies with the potential to convert them into meaningful therapies for patients. This is achieved by combining targeting motifs/sequences with potent chemotherapeutics on the same GNP nanoparticle, thus maximising tumour effects while minimising effects on normal cells. Successful constructs are expected to be ready for testing in humans during the course of 2017/18.

R&D
R&D
Glioblastoma (GBM)

Glioma of the brain in either children or adults are amongst the most aggressive cancers, with very limited and poor treatment options that are either ineffective or too toxic to be of benefit to patients. Survival is in the region of 9 – 12 months, and less than 5% survive through to 5 years. Midatech GNPs and other agents are being designed and/or evaluated for their ability to treat brain tumours via both systemic administration and/or local delivery directly into the tumour. Systemically, GNP’s may take targeting and therapeutic agents across the Blood Brain Barrier (BBB) when agents are administered intravenously. In addition to this systemic approach, Midatech is actively pursuing local delivery directly into the tumour through a technique referred to as Convection Enhanced Delivery (CED). CED bypasses the BBB and delivers therapeutic constructs directly into the tumour via a series of catheters fixed into the substance of the tumours.
 
The developed GNP constructs thus are capable of modifying both the efficacy and toxicity profile of existing therapies with the potential to convert them into meaningful therapies for patients. This is achieved by combining targeting motifs/sequences with potent chemotherapeutics on the same GNP nanoparticle, thus maximising tumour effects while minimising effects on normal cells. Successful constructs are expected to be ready for testing in humans during the course of 2017/18.

© Copyright 2017 Midatech Pharma PLC